
Lumos Pharma, Inc. – NASDAQ:LUMO
Lumos Pharma stock price monthly change
Lumos Pharma stock price quarterly change
Lumos Pharma stock price yearly change
Lumos Pharma key metrics
Market Cap | 37.53M |
Enterprise value | N/A |
P/E | -0.93 |
EV/Sales | -18.20 |
EV/EBITDA | 0.91 |
Price/Sales | 18.41 |
Price/Book | 0.47 |
PEG ratio | 0.56 |
EPS | -4.59 |
Revenue | 1.52M |
EBITDA | -39.42M |
Income | -37.12M |
Revenue Q/Q | -76.12% |
Revenue Y/Y | -27.48% |
Profit margin | -2039.53% |
Oper. margin | -2103.74% |
Gross margin | 0% |
EBIT margin | -2103.74% |
EBITDA margin | -2584.98% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeLumos Pharma stock price history
Lumos Pharma stock forecast
Lumos Pharma financial statements
Jun 2023 | 527K | -8.93M | -1694.69% |
---|---|---|---|
Sep 2023 | 7K | -8.3M | -118571.43% |
Dec 2023 | 826K | -9.45M | -1144.92% |
Mar 2024 | 165K | -10.44M | -6327.88% |
Mar 2024 | 165K | -10.44M | -6327.88% |
---|---|---|---|
Sep 2025 | 1.17M | -7.29M | -619.95% |
Oct 2025 | 223.38K | -3.16M | -1415.01% |
Dec 2025 | 19.57M | -2.99M | -15.32% |
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 56373000 | 12.71M | 22.55% |
---|---|---|---|
Sep 2023 | 47751000 | 12.25M | 25.67% |
Dec 2023 | 40638000 | 13.33M | 32.81% |
Mar 2024 | 28078000 | 10.63M | 37.89% |
Jun 2023 | -6.68M | 1.08M | -574K |
---|---|---|---|
Sep 2023 | -7.82M | 5.95M | -435K |
Dec 2023 | -7.39M | 6.17M | 742K |
Mar 2024 | -12.89M | 1M | -5K |
Lumos Pharma alternative data
Aug 2023 | 33 |
---|---|
Sep 2023 | 32 |
Oct 2023 | 32 |
Nov 2023 | 32 |
Dec 2023 | 32 |
Jan 2024 | 32 |
Feb 2024 | 32 |
Mar 2024 | 33 |
Apr 2024 | 33 |
May 2024 | 33 |
Jun 2024 | 33 |
Jul 2024 | 33 |
Lumos Pharma other data
Period | Buy | Sel |
---|---|---|
Sep 2022 | 4469 | 0 |
Nov 2022 | 4000 | 0 |
Feb 2023 | 0 | 439 |
Apr 2023 | 0 | 2214 |
Aug 2023 | 0 | 3407 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Sale | MCKEW JOHN C. officer: Chief Sc.. | Common Stock | 3,407 | $3.21 | $10,919 | ||
Sale | MCKEW JOHN C. officer: Chief Sc.. | Common Stock | 2,214 | $3.27 | $7,240 | ||
Sale | MCKEW JOHN C. officer: Chief Sc.. | Common Stock | 439 | $3.53 | $1,550 | ||
Purchase | MCCRACKEN JOSEPH S director | Common Stock | 4,000 | $5.03 | $20,120 | ||
Purchase | HAWKINS RICHARD J director, officer.. | Common Stock | 208 | $8.8 | $1,830 | ||
Purchase | HAWKINS RICHARD J director, officer.. | Common Stock | 2,214 | $8.84 | $19,572 | ||
Purchase | HAWKINS RICHARD J director, officer.. | Common Stock | 1,506 | $8.75 | $13,178 | ||
Purchase | HAWKINS RICHARD J director, officer.. | Common Stock | 541 | $8.65 | $4,680 | ||
Purchase | MCCRACKEN JOSEPH S director | Common Stock | 3,170 | $8.6 | $27,262 | ||
Purchase | RAFFIN THOMAS A. director | Common Stock | 1,150 | $8.46 | $9,729 |
Patent |
---|
Application Filling date: 24 Jan 2022 Issue date: 12 May 2022 |
Application Filling date: 21 Dec 2020 Issue date: 14 Oct 2021 |
Application COMPOSITIONS FOR THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS Filling date: 14 Feb 2019 Issue date: 4 Mar 2021 |
Grant Filling date: 20 Sep 2018 Issue date: 26 Jan 2021 |
Grant Filling date: 1 Sep 2015 Issue date: 3 Dec 2019 |
Grant Filling date: 21 Aug 2018 Issue date: 13 Aug 2019 |
Quarter | Transcript |
---|---|
Q1 2024 15 May 2024 | Q1 2024 Earnings Call Transcript |
Q4 2023 7 Mar 2024 | Q4 2023 Earnings Call Transcript |
Q2 2023 9 Aug 2023 | Q2 2023 Earnings Call Transcript |
Q1 2023 3 May 2023 | Q1 2023 Earnings Call Transcript |
Insider | Compensation |
---|---|
Mr. Richard J. Hawkins (1949) Chief Executive Officer & Chairman | $1,270,000 |
Dr. John C. McKew Ph.D. (1964) Chief Scientific Officer & Pres | $747,990 |
Mr. Carl W. Langren (1955) Consultant | $717,990 |
Mr. Bradley J. Powers J.D. (1979) Chief Compliance Officer & Gen. Counsel | $677,080 |
-
When is Lumos Pharma's next earnings date?
Unfortunately, Lumos Pharma's (LUMO) next earnings date is currently unknown.
-
Does Lumos Pharma pay dividends?
No, Lumos Pharma does not pay dividends.
-
How much money does Lumos Pharma make?
Lumos Pharma has a market capitalization of 37.53M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 34.67% to 2.05M US dollars.
-
What is Lumos Pharma's stock symbol?
Lumos Pharma, Inc. is traded on the NASDAQ under the ticker symbol "LUMO".
-
What is Lumos Pharma's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Lumos Pharma?
Shares of Lumos Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Lumos Pharma's key executives?
Lumos Pharma's management team includes the following people:
- Mr. Richard J. Hawkins Chief Executive Officer & Chairman(age: 76, pay: $1,270,000)
- Dr. John C. McKew Ph.D. Chief Scientific Officer & Pres(age: 61, pay: $747,990)
- Mr. Carl W. Langren Consultant(age: 70, pay: $717,990)
- Mr. Bradley J. Powers J.D. Chief Compliance Officer & Gen. Counsel(age: 46, pay: $677,080)
-
How many employees does Lumos Pharma have?
As Jul 2024, Lumos Pharma employs 33 workers.
-
When Lumos Pharma went public?
Lumos Pharma, Inc. is publicly traded company for more then 13 years since IPO on 11 Nov 2011.
-
What is Lumos Pharma's official website?
The official website for Lumos Pharma is lumos-pharma.com.
-
Where are Lumos Pharma's headquarters?
Lumos Pharma is headquartered at 4200 Marathon Boulevard, Austin, TX.
-
How can i contact Lumos Pharma?
Lumos Pharma's mailing address is 4200 Marathon Boulevard, Austin, TX and company can be reached via phone at +51 22152630.
Lumos Pharma company profile:

Lumos Pharma, Inc.
lumos-pharma.comNASDAQ
30
Biotechnology
Healthcare
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
Austin, TX 78756
CIK: 0001126234
ISIN: US55028X1090
CUSIP: 55028X109